Delving into the Latest Updates on Hangzhou Shengyu Biomedical Technology Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Skin and Musculoskeletal Diseases

Urogenital Diseases

Small molecule drug

Chemical drugs

Proteolysis-targeting chimeras (PROTAC)

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	9
Endocrinology and Metabolic Disease	2

Top 5 Drug Type	Count

Small molecule drug	6
Chemical drugs	2
Proteolysis-targeting chimeras (PROTAC)	1

Top 5 Target	Count

PARG(Poly(ADP-ribose) glycohydrolase)	2
POLQ(DNA polymerase theta)	2

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 18 Nov 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

4

2

Preclinical

IND Application

1

2

Phase 1

Other

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

SYN818 ( POLQ )	Locally Advanced Malignant Solid Neoplasm More	Phase 1
SYN608 ( PARG )	Locally Advanced Malignant Solid Neoplasm More	Phase 1
SY-001	Solid tumor More	IND Application
SYX-1097 ( POLQ )	Neoplasms More	Preclinical
SYX3759 ( PARG )	Neoplasms More	Preclinical